ISA to Present Results of Randomized Phase II Study of ISA101b in Head and Neck Cancer at the ASCO Annual Meeting 2024

ISA Pharmaceuticals to present at the ASCO Annual Meeting 2024

ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines